Immunotherapy Combination Sets a New Standard of Care for Extensive-Stage Small Cell Lung Cancer
3 Articles
3 Articles
Immunotherapy combination sets a new standard of care for extensive-stage small cell lung cancer
In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase 3 open-label, multicenter, randomized DeLLphi-305 study, which was presented by Jacob…
Phase 3 study DeLLphi-305 showed that tarlatamabe+durvalumabe increased survival from 12.7 to 21.1 months and reduced the risk of death by 58%.
Additional treatment with the antibody tarlatamab provided a full eight months of increased survival in patients with advanced small cell lung cancer, according to a new study presented at the Esmo Congress in Madrid.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
